Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy Volunteers-Reference-Cited by-同舟云学术

Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy Volunteers

Published:2023-12-20 Issue:1 Volume:49 Page:101-109
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Eur J Drug Metab Pharmacokinet

Author:

Stoll Felicitas^ORCID,Blank Antje,Mikus Gerd,Czock David,Weiss Johanna,Meyer-Tönnies Marleen J.,Gümüs Katja S.,Tzvetkov Mladen,Burhenne Jürgen,Haefeli Walter E.

Funder

Universitätsklinikum Heidelberg

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s13318-023-00872-2.pdf

Reference33 articles.

1. Axfors C, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12(1):2349.

2. Seguin DJ, et al. Polypharmacy and potentially inappropriate medication use in older adults with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2023;75:356–364.

3. Gomides APM, et al. High levels of polypharmacy in rheumatoid arthritis—a challenge not covered by current management recommendations: data from a large real-life study. J Pharm Pract. 2021;34(3):365–71.

4. Jack JD, et al. Polypharmacy in Middle-European rheumatoid arthritis-patients: a retrospective longitudinal cohort analysis with systematic literature review. Front Med (Lausanne). 2020;7: 573542.

5. Roodenrijs NMT, et al. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis. 2018;77(12):1705–9.